Research Funding

R01 HL133575-01 (Raffai: Principal Investigator)

6/01/2016 - 4/30/2020

National Institutes of Health 

 $250,000 direct/yr

Hyperglycemia and MicroRNA Dysregulation of Inflammation in Atherosclerosis                         

  $1,000,000 total

This project will test our hypothesis that hyperglycemia accelerates atherosclerosis in diabetic mice by dysregulating microRNA processing in immune cells as a consequence of increased cellular oxidative stress. It will also test whether this effect can be overcome by enhancing anti-oxidant capacity in immune cells to restore normal microRNA-regulated biological function and whether a metabolic memory of hyperglycemia remains imprinted in the hematopoietic system to maintain inflammation and accelerated atherosclerosis even after blood glucose control. 

Grant in Aide  16GRNT27640007  (Principal Investigator: Raffai)   

1/01/16 – 12/30/17

American Heart Association

$63,000 direct/yr

Hyperglycemia Dysregulation of MicroRNA in Myeloid cells: Impact on Atherosclerosis Regression

$126,000 total

This project will test our hypothesis that hyperglycemia accelerates atherosclerosis in diabetic mice by dysregulating microRNA processing in immune cells as a consequence of increased cellular oxidative stress. It will also test whether this effect can be overcome by enhancing anti-oxidant capacity in immune cells to restore normal microRNA-regulated biological function and whether a metabolic memory of hyperglycemia remains imprinted in the hematopoietic system to maintain inflammation and accelerated atherosclerosis even after blood glucose control.

Pilot & Feasibility Award (Raffai: Principal Investigator)

 2/01/16 – 1/31/17

UCSF Diabetes Center 

   $50,000 direct/yr

Diabetic Hyperglycemia & Altered Immunity in Atherosclerosis Regression

 $50,000 total

This project, performed in collaboration with members of the UCSF DRC, will explore the feasibility of testing whether hyperglycemia alters hematopoiesis and immunity to impair atherosclerosis regression in diabetic mice with established atherosclerosis that are subjected to plasma lipid lowering.

1U19 CA179512   (Blelloch, overall PI) (Raffai, PI research core)

9/1/13 – 8/31/18

NIH Common Fund     

$62,000 direct/yr

In Vivo Regulated Release and Function of Extracellular Small RNAs

 $310,000 total

This U19 Center’s long-term goal is to uncover paradigms of extracellular small RNA function in health and disease and apply those paradigms to clinically relevant settings including biomarker discovery and therapeutic intervention. As leader of the Research Core, Dr. Raffai will ensure the purification of exRNA in the form of lipoproteins, exosomes, microvesicles and protein-associated exRNA from cell culture media and from biological fluids including mouse and human plasma for their use in all four research projects.

1U01HL126493-01 (Woodruff, PI) (Raffai R Co-I)     

08/01/14 – 04/30/19 

NIH Common fund

 $47,000 direct/yr

Defining A Comprehensive Reference Profile of Circulating Human Extracellular RNA 

 230,300 total

Dr. Raffai will be responsible to conduct his portion of the proposed research that will involve setting up reference standards for the reproducible purification of circulating RNA associated or devoid of lipid and lipoproteins in human plasma samples. 

X